Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR

被引：0
|
作者：
Junttila, M. R. [1 ]
Warne, R. [1 ]
Repellin, C. [1 ]
Sambucetti, L. [1 ]
Chang, J. [2 ]
Kim, S. [3 ]
Kim, H. Y. [3 ]
Shin, D. G. [3 ]
Park, D. H. [3 ]
Patel, R. [4 ]
Maneval, E. Chow [4 ]
Multani, P. S. [4 ]
Daemen, A. [5 ]
Friedman, L. [6 ]
机构：
[1] ORIC Pharmaceut Inc, Dept Biol, South San Francisco, CA USA
[2] ORIC Pharmaceut Inc, DMPK, South San Francisco, CA USA
[3] Voronoi Inc, Incheon, South Korea
[4] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA
[5] ORIC Pharmaceut Inc, Translat Med Dept, South San Francisco, CA USA
[6] ORIC Pharmaceut Inc, Res Dept, South San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1345P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
    Wakelee, H.
    Soria, J.
    Camidge, R.
    Gadgeel, S.
    Goldman, J.
    Varga, A.
    Solomon, B.
    Papadimitrakopoulou, V.
    Kaur, P.
    Sequist, L. V.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S38 - S38
  • [22] FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
    Soria, Jean-Charles
    Sequist, Lecia V.
    Gadgeel, Shirish
    Goldman, Jonathan
    Wakelee, Heather
    Varga, Andrea
    Fidias, Panagiotis
    Wozniak, Antoinette J.
    Neal, Joel W.
    Doebele, Robert C.
    Garon, Edward B.
    Jaw-Tsai, Sarah
    Caunt, Lisa
    Kaur, Paramjit
    Rolfe, Lindsey
    Camidge, D. Ross
    Allen, Andrew
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S141 - S142
  • [23] First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)
    Sequist, Lecia V.
    Soria, Jean-Charles
    Gadgeel, Shirish M.
    Wakelee, Heather A.
    Camidge, D. Ross
    Varga, Andrea
    Solomon, Benjamin J.
    Papadimitrakopoulou, Vassiliki
    Jaw-Tsai, Sarah S.
    Caunt, Lisa
    Kaur, Paramjit
    Rolfe, Lindsey
    Allen, Andrew R.
    Goldman, Jonathan Wade
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Discovery of TRX-211-399, a potent, CNS-penetrant, highly selective inhibitor of EGFR exon 20 insertion mutations
    Chun, Kwangwoo
    Lim, Sumin
    Lee, Joohyun
    Choi, Seulgi
    Kim, Seongrak
    Choi, Youngil
    Park, Areum
    Kim, Bohee
    Park, Yongseo
    Choi, Eunhyun
    Lee, Sungwon
    Lee, Koo
    CANCER RESEARCH, 2024, 84 (06)
  • [25] Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
    Floc'h, Nicolas
    Martin, Matthew J.
    Riess, Jonathan W.
    Orme, Jonathan P.
    Staniszewska, Anna D.
    Menard, Ludovic
    Cuomo, Maria Emanuela
    O'Neill, Daniel J.
    Ward, Richard A.
    Finlay, M. Raymond V.
    McKerrecher, Darren
    Cheng, Mingshan
    Vang, Daniel P.
    Burich, Rebekah A.
    Keck, James G.
    Gandara, David R.
    Mack, Philip C.
    Cross, Darren A. E.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 885 - 896
  • [26] Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
    Pitts, Todd M.
    Bradshaw-Pierce, Erica L.
    Bagby, Stacey M.
    Hyatt, Stephanie L.
    Selby, Heather M.
    Spreafico, Anna
    Tentler, John J.
    McPhillips, Kelly
    Klauck, Peter J.
    Capasso, Anna
    Diamond, Jennifer R.
    Davis, S. Lindsey
    Tan, Aik Choon
    Arcaroli, John J.
    Purkey, Alicia
    Messersmith, Wells A.
    Ecsedy, Jeffery A.
    Eckhardt, S. Gail
    ONCOTARGET, 2016, 7 (31) : 50290 - 50301
  • [27] Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor
    Udagawa, Hibiki
    Hasako, Shinichi
    Ohashi, Akihiro
    Abe, Naomi
    Haruma, Tomonori
    Komori, Toshiharu
    Terasaka, Miki
    Fujita, Ryoto
    Funabashi, Kaoru
    Yasuda, Hiroyuki
    Miyadera, Kazutaka
    Goto, Koichi
    Costa, Daniel B.
    Kobayashi, Susumu S.
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies
    Liu, Zhi
    Jiang, Kailong
    Liu, Yan
    Li, Junfei
    Huang, Siqi
    Li, Ping
    Xu, Lei
    Xu, Xiaomin
    Hu, Xiaobei
    Zeng, Xia
    Huang, Zehui
    Zhou, Yubo
    Li, Jia
    Long, Kai
    Wang, Mingliang
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (15) : 12735 - 12759
  • [29] Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations
    Sun, Yuting
    Andrews, Kristin L.
    Tangpeerachaikul, Anupong
    Nguyen, Tuan M.
    Gerard, Baudouin
    Kohl, Nancy E.
    Horan, Joshua C.
    Pelish, Henry E.
    CANCER RESEARCH, 2024, 84 (06)
  • [30] NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models
    Andrews, K. L.
    Sun, Y.
    Gerard, B.
    Tangpeerachaikul, A.
    Mente, S.
    Kemper, R. A.
    Martin, C. M.
    Kohl, N. E.
    Horan, J. C.
    Pelish, H. E.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S76 - S77
12345